A Study of TopSpin360 Training Device

Sponsor
Mayo Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT06052553
Collaborator
(none)
60
1
2
26.8
2.2

Study Details

Study Description

Brief Summary

This research is being done to investigate the novel neck strengthening device, TopSpin360 and its effectiveness on measures of neck strength and cognitive function

Condition or Disease Intervention/Treatment Phase
  • Device: TopSpin360
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
The Effectiveness of a Novel Neck Training Device on Objective Neck Strength and Cognitive Measures in Junior A Hockey Players
Actual Study Start Date :
Sep 9, 2023
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 2, 2025

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control Group

Subjects will receive no intervention for the duration of the hockey season.

Experimental: TopSpin360 Intervention Group

Subjects will use TopSpin360, twice- weekly and use for the duration of the hockey season.

Device: TopSpin360
Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.

Outcome Measures

Primary Outcome Measures

  1. Change in peak force [Baseline, post-season (approximately 6 months)]

    Measured by a neck isometric device, maximal load in kilograms that could be applied to head before deviation from neutral position.

  2. Change in normalized peak force [Baseline, post-season (approximately 6 months)]

    Measured by a neck isometric device, peak force divided by participant weight in kilograms.

  3. Change in force steadiness [Baseline, post-season (approximately 6 months)]

    Measured by a neck isometric device, average peak force.

  4. Change in rate of force development (RFD) [Baseline, post-season (approximately 6 months)]

    Automatically collected by the TopSpin360 device, the multi-planar rate of force development (RFD) in pounds of force per second collected in both clockwise and counterclockwise.

  5. Change in visuo-motor reaction time [Baseline, post-season (approximately 6 months)]

    Measured by a neck isometric device, reported in milliseconds (ms)

  6. Change in blood biomarker levels [Baseline, post-season (approximately 6 months)]

    Blood will be at a biomarker level. We will investigate 5 different markers: NfL, SNCB, vWF, SNCA, and BDNF.

  7. Change in salivary biomarkers [Baseline, post-season (approximately 6 months)]

    Salivary biomarkers are relatively new and we will investigate to see if NfL, SNCB, vWF, SNCA, and BDNF.

  8. Change in N100 Amplitude [Baseline, post-season (approximately 6 months)]

    Electroencephalograph (EEG) recording of brain electrical activity N100 potential amplitude. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.

  9. Change in N100 Latency [Baseline, post-season (approximately 6 months)]

    Electroencephalograph (EEG) recording of brain electrical activity N100 potential latency. Increased latencies are indicative of slower responses. Obtained by EEG recording of N100 potential amplitude. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.

  10. Change in P300 Amplitude [Baseline, post-season (approximately 6 months)]

    Electroencephalograph (EEG) recording of brain electrical activity P300 potential amplitude. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.

  11. Change in P300 Latency [Baseline, post-season (approximately 6 months)]

    Electroencephalograph (EEG) recording of brain electrical activity P300 potential latency. Increased latencies are indicative of slower responses. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores

  12. Change in N400 Amplitude [Baseline, post-season (approximately 6 months)]

    Electroencephalograph (EEG) recording of brain electrical activity N400 potential amplitude. Increased amplitudes are indicative of larger signals. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.

  13. Change in N400 Latency [Baseline, post-season (approximately 6 months)]

    Electroencephalograph (EEG) recording of brain electrical activity N400 potential latency. Increased latencies are indicative of slower responses. This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.

Secondary Outcome Measures

  1. Change in King-Devick Test (KDT) scores [Baseline, post-season (approximately 6 months)]

    A rapid number-naming test that requires individuals to read 3 numbered patters aloud as fast as possible, the resulting time if the KDT score. The post-season score is compared to the pre-season baseline. An increase in the number of seconds required to read the 3 number patterns is considered to be significant.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Fluent English Speaker.

  • Medically cleared to play ice hockey.

Exclusion Criteria:
  • Clinically documented hearing issues.

  • In-ear hearing aid or cochlear implant.

  • Implanted pacemaker or defibrillator.

  • Metal or plastic implants in skull. lack of verbal fluency in the English language.

  • History of seizures.

  • Allergy to rubbing alcohol or EEG gel.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: Michael Stuart, MD, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Michael J. Stuart, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT06052553
Other Study ID Numbers:
  • 23-005197
First Posted:
Sep 25, 2023
Last Update Posted:
Sep 25, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Michael J. Stuart, Principal Investigator, Mayo Clinic

Study Results

No Results Posted as of Sep 25, 2023